Contents

Search

pazopanib (Votrient)

Indications: - chemotherapy for advanced renal cell carcinoma - soft tissue sarcoma [3] Dosage: tablets: 200 mg Monitor: - liver function tests (serum ALT, serum bilirubin) at baseline, at least every 4 weeks for the 1st 4 months, then periodically [2] Drug interactions: - inhibits CYP2C8, CYP2D6 & CYP3A4 Mechanism of action: - VEGF inhibitor

General

small inhibitory antineoplastic agent (ib drug)

References

  1. Prescriber's Letter 17(2): 2010 New Drugs Approved by the FDA in 2009 Detail-Document#: 260213 (subscription needed) http://www.prescribersletter.com
  2. Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: 260704 (subscription needed) http://www.prescribersletter.com
  3. Deprecated Reference